So I guess it’s Monday, or not at all and we wait for the interims? |
 Wearing my stuck record hat, I'd once again point out that the volume today (just over 3k in the first hour) indicates that there is nothing out there at the moment (good or bad) to drive it, meaning that any price movements aren't really going to tell us anything.
I think on the upside it does tell us that there is no institutional seller out there at the moment dripping out a sale, so that's my glass half full take - but overall OXB haven't done much of anything of late to stimulate that interest with news.
I hope for news every day, but my expectation is a different kettle of fish. I think if we get to Wednesday next week (end of July of course) without the quarterly business update with promised KPI table, then they will just run until the interims at the end of September.
If you look back to last year then we had nothing at all between the FY results presentation and the interim results presentation apart from the extension RNS with Cabaletta at the end of August. That was a great deal and good to see, but to the outside world that was all OXB had won since the FY results.
At the interims they told us that in the first 6 months they had gone from 18 partners and 30 programmes to 24 clients and 41 programmes.
So 8 new clients which they didn't / couldn't mention until the interims and another 11 programmes including the extension to Cabaletta.
It was very positive but they chose to keep quiet about it until the results. If they did the same again this September then it wouldn't surprise me at all. |
Pity CFC1 is no longer posting as "Blue is the colour". |
There's not much blue around today so it should get noticed. |
Looking good. Onwards upwards. |
breaking to the upside |
It's easy to forget these have more than doubled from their lows. The share price was always going to need to form structure, this is a good thing, and when we get the catalyst 420s should be the next level. |
I have to say, when i initially saw there ware 2 RNS's this morning, prior to reading, my heart lept, i thought this is the big one. Who would be a trader eh. Love it!!!!! |
7,890 shares traded as I type.
We have seen the previous explanation of their new policy re not announcing new contracts unless it's unavoidable (i.e. they are large enough to change guidance and / or the client specifically wants to), but this policy of running silent could well be the biggest factor in the seeming disinterest from the market.
So as of today IM have their rep watching their investment as a non-exec just like Novo have theirs, which is great for Novo and IM as they get regular briefings from Roch.
We have something from IR at OXB saying that they definitely might be intending to report quarterly with the KPI table at some point, even though you won't find anything that binding in the official OXB presentations.
I'm not for a minute here suggesting that they are avoiding reporting for negative reasons, as bizarrely all available evidence seems to point to the contrary, but busy or not they should have put the table out with the state of play. |
It is a good article and a nice mention of T-Charge too.
Just a reminder though that whilst our LentiVector is the tool used to alter the T-Cells in a lot of CAR-T treatments in various stages of development, it's far from the only use for LentiVector.
On my little list we are partnered with at least 7 CAR-T companies, two of which are Novartis (commercial) and another we are about to learn the name of as it goes commercial, but I think it's important to note that we had 35 partners back in April with 5 late stage programmes. There will be a lot of non CAR-T work in the remainder of those 35+ partners. |
Excellent article, many thanks |
FDA blasts Indian CDMO |
12,514 shares traded by 13:47 which is as close to nothing as doesn't matter.
Must be something to do with the whipped up vortex of anticipation. |
They need to release their promised quarterly results - with or without whatever else they might be waiting for.If they don't do that in the next 7 days then they will release quarterly figures in August and half year figures in September.It will not only make them look daft, but also their promises to make up for no routine contract win news with a regularly updated KPI table in line with cdmo industry norms.At the moment all we know of late is that Stuart is being replaced with no explanation, leaving us to come up with our own possibilities.When Frank gave us that little run of updates around the turn of the year I had great hopes it was an indication of his desire to keep us more informed. These days I think it more likely that was purely because of normal delays in France with the ABL deal and not a new normal. |
Agatha Christie detective level stuff...following this share until more is revealed :) |
'We are currently recruiting for a Talent Acquisition Specialist (UK and France) to join the Human Resources team, initially for a 12 month fixed term contract. The purpose of this role is to partner closely with assigned senior level stakeholders, acting as an advisor and taking ownership for the end-to-end recruitment lifecycle, from recruitment briefing meeting, advertising, sourcing, arranging interviews and making job offers, negotiating and agreeing final packages. The scope of recruitment will include from junior to director level roles.' (17 July 2024)
OXB's gearing up for something, not gearing down. |
Really smart chart !I'm guessing our secret customers must be within this universe?HTTps://x.com/yaireinhorn/status/1815446952395325528?s=19 |
The pandemic was a mad time Phil. They dropped money on the UK public whilst drastically curtailing what it could be spent on and you can see a lot of it pouring into the stock market. I think it's probably fair to say that we saw it pour out too. With the benefit of hindsight then all the signs were there that the world had gone mad, but I'd seen notes for £21.50 and £24 based upon the mass vaccinations going on much longer which led me to hold on. As they say, it's important to not make the same mistake twice but I'm hoping that there won't be any more pandemics like that one to give me the opportunity.
Fortunately we seem to be almost back to normality now.
Our record year as you mention was £142.8m revenue in 2021 with the vast majority of that coming from exceptional pandemic work.
This year Stuart has guided £126m to £134m but it's still far from impossible that we could yet beat that record pandemic year revenue with non-pandemic work. Next year they will smash it for sure, but there's still time left this year.
An announcement would help ;) |
Makes sense Harry, I calculated that we also reached about x9 sales in Sept 2021 with £143ish revenue and £15 a share on 86m shares at the time. |
Thought for the day number 4,536.
Mentioned many times in the past about simple CDMO sector sales multiple valuations (much easier to value than drug discovery biotech as there are far fewer variables / future predictions to consider) and also the premium on top of that valuation if an approach comes.
This news story was in my feed last night and I thought it a good example:-
So, on the speciality side of CDMO - but not pure CGT like OXB - and taken out for 8x sales.
I still think that there is only one possible buyer for OXB and that they already own 12% and that Blackrock have noted the same speech. I also agree with what has been said in the past that pure CGT is worth much more than a simple CDMO sector average, but...
OXB on their market cap today of £341m is on a multiple of 2.5x guided sales this year. Less than half the industry sector average which includes people knocking out generics.
2025 sales should easily exceed £180m and better our best ever covid year without any of that exceptional vaccine revenue. |
I always look for the upside boadicea, but so many people have reminded me over the years (correctly) that if the volume isn't there to back up any price action then it's usually nothing significant.
If there are a load of big delayed trades posted later then fair enough, but at the moment I'd go with it just being one of those things. |
It's the bid that's pushing up the price, so they show as sells in advfn terms. Doesn't that indicate that it's institutional buying, not retail? |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
